phrykt

Dyne Therapeutics, Inc. (DYN): who owns it and who trades it

As of Nov 16, 2026, DYN insiders reported 126 open-market sales worth $169M and 8 purchases worth $315K in the last 12 months, with 77% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason P Rhodes (Director), with $129M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Dyne Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DYN

246 funds and institutions reported DYN shares worth $4.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 21.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

T. Rowe Price Investment Management, Inc.21.6%
BlackRock, Inc.8.7%
Jupiter Topco LLC8.4%
FMR LLC (Fidelity)7.8%
State Street Corp5.2%
Orbis Allan Gray Ltd4.9%
Atlas Venture Life Science Advisors, LLC4.8%
Vanguard Capital Management LLC4.4%
TCG Crossover Management, LLC3.2%
Vanguard Portfolio Management LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
T. Rowe Price Investment Management, Inc.30.91M21.64%$687M+0%
BlackRock, Inc.12.40M8.69%$276M+6%
Jupiter Topco LLC12.00M8.40%$267M–
FMR LLC (Fidelity)11.21M7.85%$249M+26%
State Street Corp7.46M5.22%$166M+12%
Orbis Allan Gray Ltd7.01M4.91%$156M+4%
Atlas Venture Life Science Advisors, LLC6.80M4.76%$151M-26%
Vanguard Capital Management LLC6.31M4.42%$140M-1%
TCG Crossover Management, LLC4.62M3.23%$103MNo change
Vanguard Portfolio Management LLC4.05M2.83%$89.9M-3%
T. Rowe Price Associates3.94M2.76%$87.4M+69%
Fcpm III Services B.v.3.85M2.69%$85.5M-17%
Geode Capital Management, LLC3.74M2.62%$83.2M+7%
Vestal Point Capital, LP3.38M2.36%$75M-16%
Orbimed Advisors LLC3.24M2.27%$71.9M+11%
Frazier Life Sciences Management, L.P.3.15M2.21%$70MNo change
JPMorgan Chase & Co3.15M2.21%$67.2M–
Armistice Capital, LLC3.09M2.16%$68.6M-3%
California State Teachers Retirement System3.00M2.10%$135M+2049%
Perceptive Advisors LLC2.69M1.88%$59.7M-42%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DYN insiders reported $315K of open-market purchases and $169M of sales. 77% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$315K
8 trades, 1 people
Sales, 12 months
$169M
126 trades, 6 people
Sales under a 10b5-1 plan
77%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$65.4M$65.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026John CoxCEOSale plan5,513$16.82$92.7KForm 4
Nov 13, 2026Erick LuceraCFOSale plan1,991$16.82$33.5KForm 4
Nov 13, 2026Douglas KerrHead of R&D and CMOSale plan2,604$16.82$43.8KForm 4
Nov 13, 2026Johanna Friedl-NadererChief Commercial OfficerSale plan231$16.82$3.9KForm 4
Oct 2, 2026Brian S PosnerDirectorPurchase2,500$16.00$40KForm 4
Sep 8, 2026Johanna Friedl-NadererChief Commercial OfficerSale185$18.88$3.5KForm 4
Sep 8, 2026Douglas KerrChief Medical OfficerSale1,290$18.88$24.4KForm 4
Sep 8, 2026John CoxCEOSale5,658$18.88$107KForm 4
Sep 4, 2026Johanna Friedl-NadererChief Commercial OfficerSale900$24.35$21.9KForm 4
Sep 4, 2026Douglas KerrChief Medical OfficerSale3,745$24.35$91.2KForm 4
Aug 14, 2026Jason P RhodesDirectorSale plan1.36M$25.00$34MForm 4
Aug 14, 2026Jason P RhodesDirectorSale plan478,377$25.00$12MForm 4
Aug 14, 2026Jason P RhodesDirectorSale plan322,465$25.00$8.1MForm 4
Aug 13, 2026Jason P RhodesDirectorSale plan268,354$26.20$7MForm 4
Aug 13, 2026Jason P RhodesDirectorSale plan94,415$26.20$2.5MForm 4
Aug 13, 2026Jason P RhodesDirectorSale plan63,643$26.20$1.7MForm 4
Aug 13, 2026Johanna Friedl-NadererChief Commercial OfficerSale226$26.28$5.9KForm 4
Aug 13, 2026Douglas KerrChief Medical OfficerSale1,556$26.28$40.9KForm 4
Aug 13, 2026John CoxCEOSale4,986$26.28$131KForm 4
Aug 13, 2026Erick LuceraCFOSale1,797$26.28$47.2KForm 4
Jul 27, 2026Dirk KerstenDirectorSale5,388$26.04$140KForm 4
Jul 27, 2026Dirk KerstenDirectorSale256,072$25.50$6.5MForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan62,543$23.17$1.4MForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan14,844$23.62$351KForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan49,193$23.17$1.1MForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan11,665$23.62$276KForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan29,587$23.62$699KForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan124,379$23.17$2.9MForm 4
Jul 7, 2026Jason P RhodesDirectorSale plan5,000$23.61$118KForm 4
Jul 6, 2026Jason P RhodesDirectorSale plan127,182$22.79$2.9MForm 4
Jul 6, 2026Jason P RhodesDirectorSale plan253,039$22.79$5.8MForm 4
Jul 6, 2026Jason P RhodesDirectorSale plan100,019$22.79$2.3MForm 4
Jun 29, 2026Jason P RhodesDirectorSale plan102,969$21.14$2.2MForm 4
Jun 29, 2026Jason P RhodesDirectorSale plan40,702$21.14$860KForm 4
Jun 29, 2026Jason P RhodesDirectorSale plan51,756$21.14$1.1MForm 4
Jun 26, 2026Jason P RhodesDirectorSale plan162,954$21.28$3.5MForm 4
Jun 26, 2026Jason P RhodesDirectorSale plan81,903$21.28$1.7MForm 4
Jun 26, 2026Jason P RhodesDirectorSale plan64,411$21.28$1.4MForm 4
Jun 25, 2026Erick LuceraCFOSale2,362$20.37$48.1KForm 4
Jun 25, 2026Jason P RhodesDirectorSale plan6,382$21.10$135KForm 4
Jun 25, 2026Jason P RhodesDirectorSale plan12,699$21.10$268KForm 4
Jun 25, 2026Jason P RhodesDirectorSale plan5,019$21.10$106KForm 4
Jun 24, 2026Jason P RhodesDirectorSale plan19,973$21.02$420KForm 4
Jun 24, 2026Jason P RhodesDirectorSale plan25,397$21.02$534KForm 4
Jun 24, 2026Jason P RhodesDirectorSale plan50,530$21.02$1.1MForm 4
Jun 23, 2026Jason P RhodesDirectorSale plan30,774$21.13$650KForm 4
Jun 23, 2026Jason P RhodesDirectorSale plan77,855$21.13$1.6MForm 4
Jun 23, 2026Jason P RhodesDirectorSale plan39,131$21.13$827KForm 4
Jun 23, 2026Dirk KerstenDirectorSale1,657$21.47$35.6KForm 4
Jun 23, 2026Dirk KerstenDirectorSale71,629$21.04$1.5MForm 4
Jun 22, 2026Dirk KerstenDirectorSale190,676$20.57$3.9MForm 4
Jun 18, 2026Dirk KerstenDirectorSale46,901$20.07$941KForm 4
Jun 17, 2026Dirk KerstenDirectorSale37,454$20.14$754KForm 4
Jun 16, 2026Douglas KerrChief Medical OfficerSale887$18.33$16.3KForm 4
Jun 16, 2026Johanna Friedl-NadererChief Commercial OfficerSale145$18.33$2.7KForm 4
Jun 16, 2026John CoxCEOSale2,683$18.33$49.2KForm 4
Jun 8, 2026Brian S PosnerDirectorPurchase2,000$16.94$33.9KForm 4
Jun 3, 2026Brian S PosnerDirectorPurchase2,500$17.48$43.7KForm 4
May 26, 2026Brian S PosnerDirectorPurchase2,000$18.21$36.4KForm 4
May 20, 2026Brian S PosnerDirectorPurchase2,500$17.12$42.8KForm 4
May 13, 2026Johanna Friedl-NadererChief Commercial OfficerSale228$18.36$4.2KForm 4
May 13, 2026Douglas KerrChief Medical OfficerSale1,564$18.36$28.7KForm 4
May 13, 2026Erick LuceraCFOSale1,448$18.36$26.6KForm 4
May 13, 2026John CoxCEOSale3,311$18.36$60.8KForm 4
May 6, 2026Jason P RhodesDirectorSale plan21,926$18.18$399KForm 4
May 6, 2026Jason P RhodesDirectorSale plan43,621$18.18$793KForm 4
May 6, 2026Jason P RhodesDirectorSale plan428$18.18$7.8KForm 4
May 6, 2026Jason P RhodesDirectorSale plan17,244$18.18$313KForm 4
May 5, 2026Jason P RhodesDirectorSale plan3,056$18.03$55.1KForm 4
May 5, 2026Jason P RhodesDirectorSale plan6,081$18.03$110KForm 4
May 5, 2026Jason P RhodesDirectorSale plan60$18.03$1.1KForm 4
May 5, 2026Jason P RhodesDirectorSale plan2,403$18.03$43.3KForm 4
May 4, 2026Jason P RhodesDirectorSale plan61$18.00$1.1KForm 4
May 4, 2026Jason P RhodesDirectorSale plan2,466$18.00$44.4KForm 4
May 4, 2026Jason P RhodesDirectorSale plan3,136$18.00$56.4KForm 4
May 4, 2026Jason P RhodesDirectorSale plan6,241$18.00$112KForm 4
Apr 28, 2026Jason P RhodesDirectorSale plan26$19.00$494Form 4
Apr 28, 2026Jason P RhodesDirectorSale plan52$19.00$988Form 4
Apr 28, 2026Jason P RhodesDirectorSale plan1$19.00$19Form 4
Apr 28, 2026Jason P RhodesDirectorSale plan47,082$18.38$865KForm 4
Apr 28, 2026Jason P RhodesDirectorSale plan1,170$18.38$21.5KForm 4
Apr 28, 2026Jason P RhodesDirectorSale plan21$19.00$399Form 4
Apr 28, 2026Jason P RhodesDirectorSale plan59,870$18.38$1.1MForm 4
Apr 28, 2026Jason P RhodesDirectorSale plan119,115$18.38$2.2MForm 4
Apr 27, 2026Jason P RhodesDirectorSale plan45,709$18.15$830KForm 4
Apr 27, 2026Jason P RhodesDirectorSale plan90,943$18.15$1.7MForm 4
Apr 27, 2026Jason P RhodesDirectorSale plan35,947$18.15$652KForm 4
Apr 27, 2026Jason P RhodesDirectorSale plan894$18.15$16.2KForm 4
Apr 24, 2026Jason P RhodesDirectorSale plan72,310$18.48$1.3MForm 4
Apr 24, 2026Jason P RhodesDirectorSale plan710$18.48$13.1KForm 4
Apr 24, 2026Jason P RhodesDirectorSale plan28,583$18.48$528KForm 4
Apr 24, 2026Jason P RhodesDirectorSale plan36,345$18.48$672KForm 4
Apr 23, 2026Jason P RhodesDirectorSale plan15,148$19.19$291KForm 4
Apr 23, 2026Jason P RhodesDirectorSale plan377$19.19$7.2KForm 4
Apr 23, 2026Jason P RhodesDirectorSale plan38,322$19.19$735KForm 4
Apr 23, 2026Jason P RhodesDirectorSale plan19,261$19.19$370KForm 4
Apr 22, 2026Dirk KerstenDirectorSale2,652$20.00$53KForm 4
Apr 22, 2026Jason P RhodesDirectorSale plan59,663$19.68$1.2MForm 4
Apr 22, 2026Jason P RhodesDirectorSale plan1,485$19.68$29.2KForm 4
Apr 22, 2026Jason P RhodesDirectorSale plan150,942$19.68$3MForm 4

Latest 100 of 134 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason P RhodesDirector–$129MAug 14, 2026
Dirk KerstenDirector–$38.6MJul 27, 2026
John CoxCEO & President, Director–$536KNov 13, 2026
Brian S PosnerDirector$315K–Oct 2, 2026
Douglas KerrChief Medical Officer–$277KNov 13, 2026
Erick LuceraChief Financial Officer–$262KNov 13, 2026
Johanna Friedl-NadererChief Commercial Officer–$47.3KNov 13, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DYN short interest

High short interest. 13.0% of DYN shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 16%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 24.38M DYN shares were sold short, 13.0% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 2.26M shares, buying them all back would take about 10.8 trading days (days to cover).

Shares short, % of all shares

13.0%May 15Oct 3015.2%

Days to cover

10.8May 15Oct 3018.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202624.38M13.01%-4%2.26M10.8
Oct 15, 202625.47M13.64%-2%3.44M7.4
Sep 30, 202625.98M13.91%+11%2.88M9.0
Sep 15, 202623.38M12.52%+12%4.28M5.5
Aug 31, 202620.79M11.13%-3%1.54M13.5
Aug 14, 202621.46M11.49%-2%1.96M10.9
Jul 31, 202621.97M11.76%+2%3.06M7.2
Jul 15, 202621.49M–-4%2.02M10.6
Jun 30, 202622.30M–-2%2.79M8.0
Jun 15, 202622.81M–+2%1.59M14.3
May 29, 202622.28M–+6%1.52M14.6
May 15, 202620.98M14.69%+1%1.25M16.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Dyne Therapeutics company events

Dyne Therapeutics filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 29, 2026AnnouncementThe Company issued a press release and presentation announcing additional one-year clinical data from the ACHIEVE trial evaluating z-basivarsen in individuals with DM1. Filing
  3. Jul 29, 2026ResultsReleased financial results. Filing
  4. Jul 22, 2026AgreementDyne Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering of 18,300,000 shares of the Company’s common stock, par value $0.0001 per share. Filing
  5. Jul 20, 2026AnnouncementDyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. Filing
  6. Jun 22, 2026LeadershipThe Board of Directors of Dyne Therapeutics, Inc., upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been… Filing
  7. Jun 17, 2026AgreementDyne Therapeutics, Inc. entered into the Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent, and certain other financial institutions party thereto as lenders, dated as of June 27, 2025 (the “Initial Loan… Filing
  8. Jun 8, 2026VoteReported shareholder vote results. Filing
  9. Jun 3, 2026AnnouncementThe Company issued a press release announcing full enrollment of the REC of its Phase 1/2 ACHIEVE trial of z-basivarsen in individuals with DM1 with 71 participants. Filing
  10. May 11, 2026ResultsReleased financial results. Filing
  11. Mar 2, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026ResultsReleased financial results. Filing
  13. Dec 23, 2025LeadershipThe Board of Directors of Dyne Therapeutics, Inc., upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders and until his successor has been… Filing
  14. Dec 10, 2025AgreementDyne Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering of… Filing
  15. Dec 8, 2025DebtTook on new debt. Filing
  16. Dec 8, 2025AnnouncementThe Company issued a press release announcing positive topline results from the REC of its DELIVER trial evaluating z-rostudirsen in individuals with DMD amenable to exon 51 skipping. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Dyne Therapeutics financials

Famous investors that hold DYN

5 of the 50 well-known investors we track reported holding DYN in their latest 13F filing. The largest position is Ken Griffin's, worth $31.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.95M$31.5M0.0%+71%
Israel Englander · Millennium ManagementQ3 2026466,145$7.5M0.0%+8%
Ken Fisher · Fisher Asset ManagementQ3 2026259,024$4.2M0.0%-13%
Jim Simons · Renaissance TechnologiesQ3 2026131,700$2.1M0.0%-63%
George Soros · Soros Fund ManagementQ3 202620,000$322K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DYN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Wellington Management Group LLP13G5.7%
Nov 16, 2026Wellington Management Group LLP13G5.7%

Questions about Dyne Therapeutics, Inc. (DYN) stock

Who owns the most DYN stock?

The largest reported owner of Dyne Therapeutics, Inc. (DYN) is T. Rowe Price Investment Management, Inc., with 21.6% of the company. In total, 246 funds and institutions reported holding DYN at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are DYN insiders buying or selling?

In the last 12 months, DYN insiders reported 8 open-market purchases worth $315K and 126 sales worth $169M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in DYN?

As of Oct 30, 2026, 24.38M DYN shares were sold short, 13.0% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 2.26M shares, buying them all back would take about 10.8 trading days (days to cover). See the history.

Which famous investors hold DYN?

5 of the 50 well-known investors we track reported DYN in their latest 13F filing, including Ken Griffin, Israel Englander, Ken Fisher. The largest position is worth $31.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.